Christopher Beattie
Public Communications Contact chez BLACKROCK CAPITAL INVESTMENT CORPORATION
Profil
Christopher Beattie is currently working as a Press Contact at BlackRock Capital Investment Corp.
Prior to this, he worked as a Director-Clinical & Regulatory Affairs at Onyvax Ltd.
and as a Principal at Xenova Group Plc.
Postes actifs de Christopher Beattie
| Sociétés | Poste | Début |
|---|---|---|
| BLACKROCK CAPITAL INVESTMENT CORPORATION | Public Communications Contact | - |
Anciens postes connus de Christopher Beattie
| Sociétés | Poste | Fin |
|---|---|---|
Xenova Group Plc
 Xenova Group Plc Miscellaneous Commercial ServicesCommercial Services Xenova Group Plc researches and develops pharmaceutical products. The company is focused on the development of novel drugs to treat cancer and addiction with a secondary focus in immunotherapy. It has pipeline of drug candidates in clinical development including a novel program for the treatment of high-grade glioma and TransMID. The company was founded in 1987 and is headquartered in Slough, UK | Corporate Officer/Principal | - |
Onyvax Ltd.
 Onyvax Ltd. Miscellaneous Commercial ServicesCommercial Services Onyvax Ltd. developed cancer remedy therapies. The company was founded in 1995 and was headquartered in Bradford, the United Kingdom. | Conseiller Juridique Général | 31/05/2012 |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Onyvax Ltd.
Onyvax Ltd. Miscellaneous Commercial ServicesCommercial Services Onyvax Ltd. developed cancer remedy therapies. The company was founded in 1995 and was headquartered in Bradford, the United Kingdom. | Commercial Services |
Xenova Group Plc
Xenova Group Plc Miscellaneous Commercial ServicesCommercial Services Xenova Group Plc researches and develops pharmaceutical products. The company is focused on the development of novel drugs to treat cancer and addiction with a secondary focus in immunotherapy. It has pipeline of drug candidates in clinical development including a novel program for the treatment of high-grade glioma and TransMID. The company was founded in 1987 and is headquartered in Slough, UK | Commercial Services |
BlackRock Capital Investment Corp
 BlackRock Capital Investment Corp Investment ManagersFinance BlackRock Capital Investment Corp., engages in the traded fund, seeks investment opportunities in middle market companies located in the United States and Canada with revenues of $50 million to $1 billion. The fund targets companies operating in the field of consumer services, technology, distribution, commercial services, health services, retail trade, finance, and transportation. It provides financing in the form of equity, mezzanine and debt investments with an investment size ranging from USD 10 - 50 million. The company was founded on April 13, 2005 and is headquartered in New York, NY. | Finance |
